|
| Trial | Method | Patients () | Study population | Regimen | Followup | Incidence of VTE |
| Study | Control | Study (%) | Control (%) |
|
| Bergqvist et al. 1990 [246] | Randomise double blind-trial | 637 | Patients with cancer (study subgroup) undergoing abdominal surgery | Dalteparin 5000 Units preoperatively then q.d. × 5–8 days | UFH 5000 Units 2 h preoperatively then b.d. × 5–8 days | 7 days | 6.4 | 11.2 |
| EFS 1988 [120] | Randomised trial | 704 | Patients with cancer (study subgroup) scheduled for elective abdominal surgery | Fraxiparin 7500 anti-Xa units preoperatively then q.d. × 7 days | Calcium heparin 5000 units preoperatively then t.i.d × 7 days | 7 days | | |
| Enoxacan 1997 [229] | Double-blind randomised trial | 631 | Patients undergoing planned curative abdominal or pelvic surgery for cancer (study subgroup) | Enoxaparin 40 mg q.d. × 10 days | Low-dose UFH t.i.d × 10 days | 3 months | 14.7 | 18.2 |
| Fricker et al. 1988 [247] | Randomised trial | 80 | Patients with cancer undergoing surgery for abdominal and pelvic malignancy | 2500 anti-Xa Units 2 h before surgery and 12 h after the first injection and then 5000 anti-Xa Units fragmin injection q.d. × 10 days | 5000 IU of calcium heparin injection 2 h before the surgery and then t.i.d × 10 days | 10 days | 5 | 5 |
| Godwin et al. 1993 [248] | Double-blind randomised trial | 904 | Patients undergoing abdominal or pelvic cancer surgery | RDH (Normiflo) 50 U 2 h preoperatively and then 90 U q.d./bd | UFH 5000 U 2 h preoperatively and then 5000 U b.d. | | | |
| McLeod et al. 2001 [249] | Randomise double-blind trial | 324 | Patients with cancer undergoing colorectal cancer surgery | Enoxaparin 40 mg q.d. × 10 days | Heparin 5000 U t.i.d. × 10 days | 10 days | 13.9 | 16.9 |
| Onarheim et al. 1986 [250] | Randomised double-blind trial | 52 | Patients undergoing surgery for abdominal malignancy | Dalteparin 5000 U 2 h preoperatively then q.d. × 6 days | Heparin Kabi2165 5000 U 2 h preoperatively then b.d. × 6 days | 7 days | 1.92 | 3.84 |
|
